Business
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabi
About this update from Polyrizon Ltd.
[{"type":"text","content":"Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product.","length":367,"tagName":"p"},{"type":"text","content":"The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. The laboratory specializes in the research and development of intranasally administered technologies.","length":244,"tagName":"p"},{"type":"text","content":"The evaluation was performed using a validated silicone nasal cast model (Koken® LM-005) combined with quantitative image analysis. Results demonstrated that Polyrizon’s formulation achieved significantly higher deposition in the nasal vestibule region compared to the commercial reference product.","length":298,"tagName":"p"},{"type":"text","content":"Key Findings:","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Polyrizon’s advanced nasal formulation achieved 94.6% (±4.0%) deposition in the nasal vestibule and upper turbinate, a highly vascularized region that may support rapid systemic absorption and potentially enhance the onset and bioavailability of intranasally administered drugs.","length":278,"tagName":"p"}]},{"val":[{"type":"text","content":"In comparison, the reference commercial product delivered only 79.6% (±3.0%) to the same nasal cavity area.","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Polyrizon’s formulation also showed significantly lower deposition in the lower turbinate region (5.4% vs. 20.4% for the commercial product), potentially reducing posterior runoff and unintended drainage toward the nasopharynx, which may support improved dosing consistency and systemic delivery efficiency.","length":307,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":692,"olType":false},{"type":"text","content":"The upper/anterior nasal region (upper turbinate and vestibule) is highly vascularized and plays a critical role in rapid systemic drug absorption. Enhanced and reproducible targeting of this region suggests that Polyrizon’s Trap & Target™ te...